Does the media refer more to TRDA or JANX?

In the previous week, Entrada Therapeutics had 2 more articles in the media than Janux Therapeutics. MarketBeat recorded 11 mentions for Entrada Therapeutics and 9 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.33 beat Entrada Therapeutics' score of 0.76 indicating that Janux Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entrada Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Janux Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TRDA or SANA?

In the previous week, Sana Biotechnology had 1 more articles in the media than Entrada Therapeutics. MarketBeat recorded 12 mentions for Sana Biotechnology and 11 mentions for Entrada Therapeutics. Sana Biotechnology's average media sentiment score of 0.85 beat Entrada Therapeutics' score of 0.76 indicating that Sana Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entrada Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sana Biotechnology 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TRDA or KURA?

In the previous week, Kura Oncology had 13 more articles in the media than Entrada Therapeutics. MarketBeat recorded 24 mentions for Kura Oncology and 11 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 0.76 beat Kura Oncology's score of 0.74 indicating that Entrada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entrada Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kura Oncology 10 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate TRDA or CVAC?

Entrada Therapeutics currently has a consensus target price of $17.75, indicating a potential upside of 153.57%. Given Entrada Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Entrada Therapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entrada Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, TRDA or CVAC?

CureVac has higher revenue and earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Entrada Therapeutics $25.42M 10.72 -$143.75M -$3.96 N/A CureVac $70.74M 14.78 $175.50M $0.72 6.47

Does the media prefer AVTX or TRDA?

In the previous week, Entrada Therapeutics had 9 more articles in the media than Avalo Therapeutics. MarketBeat recorded 11 mentions for Entrada Therapeutics and 2 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.94 beat Entrada Therapeutics' score of 0.76 indicating that Avalo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Entrada Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Entrada Therapeutics (TRDA) Competitors

$7.00 -0.27 (-3.71%)

As of 08/28/2026 04:00 PM Eastern

Compare

TRDA vs. JANX, SANA, KURA, CVAC, and AVTX

Should you buy Entrada Therapeutics stock or one of its competitors? Entrada Therapeutics's main competitors and comparable companies include Janux Therapeutics (JANX), Sana Biotechnology (SANA), Kura Oncology (KURA), CureVac (CVAC), and Avalo Therapeutics (AVTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Entrada Therapeutics compare to Janux Therapeutics?

Entrada Therapeutics (NASDAQ:TRDA) and Janux Therapeutics (NASDAQ:JANX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

In the previous week, Entrada Therapeutics had 2 more articles in the media than Janux Therapeutics. MarketBeat recorded 11 mentions for Entrada Therapeutics and 9 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.33 beat Entrada Therapeutics' score of 0.76 indicating that Janux Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entrada Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Janux Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Entrada Therapeutics has a beta of -0.26, suggesting that its stock price is 126% less volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.5, suggesting that its stock price is 150% more volatile than the broader market.

Janux Therapeutics has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -3,537.73%. Janux Therapeutics' return on equity of -11.89% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%
Janux Therapeutics	N/A	-11.89%	-11.13%

Entrada Therapeutics currently has a consensus target price of $17.75, indicating a potential upside of 153.57%. Janux Therapeutics has a consensus target price of $36.46, indicating a potential upside of 102.23%. Given Entrada Therapeutics' higher probable upside, analysts plainly believe Entrada Therapeutics is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67

86.4% of Entrada Therapeutics shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 9.5% of Entrada Therapeutics shares are held by insiders. Comparatively, 7.9% of Janux Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Janux Therapeutics has lower revenue, but higher earnings than Entrada Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42M	10.72	-$143.75M	-$3.96	N/A
Janux Therapeutics	$10M	110.24	-$113.62M	-$1.64	N/A

Summary

Janux Therapeutics beats Entrada Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Entrada Therapeutics compare to Sana Biotechnology?

Entrada Therapeutics (NASDAQ:TRDA) and Sana Biotechnology (NASDAQ:SANA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Entrada Therapeutics has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42M	10.72	-$143.75M	-$3.96	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A

Sana Biotechnology has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -3,537.73%. Entrada Therapeutics' return on equity of -57.61% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%
Sana Biotechnology	N/A	-103.02%	-39.16%

Entrada Therapeutics presently has a consensus price target of $17.75, indicating a potential upside of 153.57%. Sana Biotechnology has a consensus price target of $9.33, indicating a potential upside of 137.49%. Given Entrada Therapeutics' higher probable upside, analysts clearly believe Entrada Therapeutics is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

86.4% of Entrada Therapeutics shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 9.5% of Entrada Therapeutics shares are held by company insiders. Comparatively, 25.4% of Sana Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Entrada Therapeutics has a beta of -0.26, suggesting that its share price is 126% less volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.16, suggesting that its share price is 116% more volatile than the broader market.

In the previous week, Sana Biotechnology had 1 more articles in the media than Entrada Therapeutics. MarketBeat recorded 12 mentions for Sana Biotechnology and 11 mentions for Entrada Therapeutics. Sana Biotechnology's average media sentiment score of 0.85 beat Entrada Therapeutics' score of 0.76 indicating that Sana Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entrada Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sana Biotechnology	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sana Biotechnology beats Entrada Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Entrada Therapeutics compare to Kura Oncology?

Entrada Therapeutics (NASDAQ:TRDA) and Kura Oncology (NASDAQ:KURA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

Entrada Therapeutics has higher earnings, but lower revenue than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42M	10.72	-$143.75M	-$3.96	N/A
Kura Oncology	$77.23M	14.58	-$278.67M	-$3.37	N/A

In the previous week, Kura Oncology had 13 more articles in the media than Entrada Therapeutics. MarketBeat recorded 24 mentions for Kura Oncology and 11 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 0.76 beat Kura Oncology's score of 0.74 indicating that Entrada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entrada Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kura Oncology	10 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Entrada Therapeutics has a beta of -0.26, suggesting that its share price is 126% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

Kura Oncology has a net margin of -384.30% compared to Entrada Therapeutics' net margin of -3,537.73%. Entrada Therapeutics' return on equity of -57.61% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%
Kura Oncology	-384.30%	-207.18%	-45.17%

86.4% of Entrada Therapeutics shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by insiders. Comparatively, 7.6% of Kura Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Entrada Therapeutics presently has a consensus price target of $17.75, suggesting a potential upside of 153.57%. Kura Oncology has a consensus price target of $25.40, suggesting a potential upside of 100.63%. Given Entrada Therapeutics' higher possible upside, equities research analysts clearly believe Entrada Therapeutics is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Summary

Kura Oncology beats Entrada Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Entrada Therapeutics compare to CureVac?

Entrada Therapeutics (NASDAQ:TRDA) and CureVac (NASDAQ:CVAC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

CureVac has a net margin of 199.92% compared to Entrada Therapeutics' net margin of -3,537.73%. CureVac's return on equity of -23.03% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%
CureVac	199.92%	-23.03%	-19.09%

86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by insiders. Comparatively, 2.2% of CureVac shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Entrada Therapeutics has a beta of -0.26, indicating that its stock price is 126% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

CureVac has higher revenue and earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42M	10.72	-$143.75M	-$3.96	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

In the previous week, Entrada Therapeutics had 11 more articles in the media than CureVac. MarketBeat recorded 11 mentions for Entrada Therapeutics and 0 mentions for CureVac. Entrada Therapeutics' average media sentiment score of 0.76 beat CureVac's score of 0.00 indicating that Entrada Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Entrada Therapeutics	Positive
CureVac	Neutral

Entrada Therapeutics currently has a consensus target price of $17.75, indicating a potential upside of 153.57%. Given Entrada Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Entrada Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

CureVac beats Entrada Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Entrada Therapeutics compare to Avalo Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by company insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Entrada Therapeutics had 9 more articles in the media than Avalo Therapeutics. MarketBeat recorded 11 mentions for Entrada Therapeutics and 2 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.94 beat Entrada Therapeutics' score of 0.76 indicating that Avalo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Entrada Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalo Therapeutics has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -3,537.73%. Entrada Therapeutics' return on equity of -57.61% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%

Avalo Therapeutics has higher earnings, but lower revenue than Entrada Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	17,510.20	-$78.26M	-$4.37	N/A
Entrada Therapeutics	$25.42M	10.72	-$143.75M	-$3.96	N/A

Avalo Therapeutics currently has a consensus price target of $45.10, suggesting a potential upside of 130.22%. Entrada Therapeutics has a consensus price target of $17.75, suggesting a potential upside of 153.57%. Given Entrada Therapeutics' higher probable upside, analysts clearly believe Entrada Therapeutics is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Avalo Therapeutics has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.26, indicating that its stock price is 126% less volatile than the broader market.

Summary

Avalo Therapeutics and Entrada Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Entrada Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRDA vs. The Competition

Export

Metric	Entrada Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$272.56M	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-1.77	11.62	273.16	25.45
Price / Sales	10.72	1,238.99	592.59	73.08
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	1.17	16.53	12.98	6.14
Net Income	-$143.75M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-7.53%	-0.31%	0.13%	-0.80%
1 Month Performance	3.40%	9.80%	7.08%	4.13%
1 Year Performance	27.97%	55.66%	24.67%	15.17%

Entrada Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRDA Entrada Therapeutics	2.4755 of 5 stars	$7.00 -3.7%	$17.75 +153.6%	+28.0%	$272.56M	$25.42M	N/A	110	News Coverage Insider Trade
JANX Janux Therapeutics	2.871 of 5 stars	$18.68 +0.4%	$36.46 +95.2%	-20.6%	$1.14B	$10M	N/A	30	News Coverage Positive News
SANA Sana Biotechnology	2.417 of 5 stars	$4.10 +8.5%	$9.33 +127.6%	+28.4%	$1.13B	N/A	N/A	380	News Coverage
KURA Kura Oncology	3.9198 of 5 stars	$13.59 +9.6%	$25.40 +86.9%	+60.3%	$1.10B	$67.48M	N/A	130	High Trading Volume
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRDA) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entrada Therapeutics (TRDA) Competitors

TRDA vs. JANX, SANA, KURA, CVAC, and AVTX

How does Entrada Therapeutics compare to Janux Therapeutics?

Summary

How does Entrada Therapeutics compare to Sana Biotechnology?

Summary

How does Entrada Therapeutics compare to Kura Oncology?

Summary

How does Entrada Therapeutics compare to CureVac?

Summary

How does Entrada Therapeutics compare to Avalo Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA vs. The Competition

Entrada Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entrada Therapeutics (TRDA) Competitors

TRDA vs. JANX, SANA, KURA, CVAC, and AVTX

How does Entrada Therapeutics compare to Janux Therapeutics?

Does the media refer more to TRDA or JANX?

Which has more risk and volatility, TRDA or JANX?

Is TRDA or JANX more profitable?

Do analysts prefer TRDA or JANX?

Do institutionals & insiders hold more shares of TRDA or JANX?

Which has preferable earnings & valuation, TRDA or JANX?

Summary

How does Entrada Therapeutics compare to Sana Biotechnology?

Which has stronger valuation & earnings, TRDA or SANA?

Is TRDA or SANA more profitable?

Do analysts prefer TRDA or SANA?

Do insiders & institutionals hold more shares of TRDA or SANA?

Which has more volatility and risk, TRDA or SANA?

Does the media refer more to TRDA or SANA?

Summary

How does Entrada Therapeutics compare to Kura Oncology?

Which has stronger earnings & valuation, TRDA or KURA?

Does the media favor TRDA or KURA?

Which has more risk & volatility, TRDA or KURA?

Is TRDA or KURA more profitable?

Do institutionals and insiders have more ownership in TRDA or KURA?

Do analysts prefer TRDA or KURA?

Summary

How does Entrada Therapeutics compare to CureVac?

Is TRDA or CVAC more profitable?

Do institutionals & insiders believe in TRDA or CVAC?

Which has more risk & volatility, TRDA or CVAC?

Which has higher earnings and valuation, TRDA or CVAC?

Does the media refer more to TRDA or CVAC?

Do analysts rate TRDA or CVAC?

Summary

How does Entrada Therapeutics compare to Avalo Therapeutics?

Do insiders & institutionals have more ownership in AVTX or TRDA?

Does the media prefer AVTX or TRDA?

Is AVTX or TRDA more profitable?

Which has stronger earnings and valuation, AVTX or TRDA?

Do analysts prefer AVTX or TRDA?

Which has more risk & volatility, AVTX or TRDA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA vs. The Competition

Entrada Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools